MXPA04001805A - Nueva forma de dosificacion oral de liberacion prolongada. - Google Patents
Nueva forma de dosificacion oral de liberacion prolongada.Info
- Publication number
- MXPA04001805A MXPA04001805A MXPA04001805A MXPA04001805A MXPA04001805A MX PA04001805 A MXPA04001805 A MX PA04001805A MX PA04001805 A MXPA04001805 A MX PA04001805A MX PA04001805 A MXPA04001805 A MX PA04001805A MX PA04001805 A MXPA04001805 A MX PA04001805A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- extended release
- release oral
- oral dosage
- new extended
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Abstract
La presente invencion se refiere a una forma nueva de dosificacion oral, de liberacion prolongada, de una sustancia farmaceuticamente activa bien soluble. Mas particularmente, la invencion se refiere a una forma de dosificacion oral, de liberacion prolongada, que proporciona un perfil de concentracion sanguineo definido, que no tiene un aumento inicial rapido en la concentracion del plasma sanguineo de la sustancia activa bien soluble cuando se administra en dosis bajas. La invencion se refiere ademas, a un proceso para preparar dicha forma de dosificacion, el uso de dicha forma de dosificacion y un metodo para la prevencion y/o tratamiento de las trastornos del SNC y alteraciones medicas relacionadas que usan la forma de dosificacion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102887A SE0102887D0 (sv) | 2001-08-29 | 2001-08-29 | New formulation |
| PCT/SE2002/001541 WO2003017983A1 (en) | 2001-08-29 | 2002-08-28 | A new extended release oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04001805A true MXPA04001805A (es) | 2004-07-08 |
Family
ID=20285178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04001805A MXPA04001805A (es) | 2001-08-29 | 2002-08-28 | Nueva forma de dosificacion oral de liberacion prolongada. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040197404A1 (es) |
| EP (1) | EP1423099A1 (es) |
| JP (1) | JP2005504052A (es) |
| KR (1) | KR20040032977A (es) |
| CN (1) | CN1549705A (es) |
| BR (1) | BR0212167A (es) |
| CA (1) | CA2457341A1 (es) |
| HU (1) | HUP0401599A3 (es) |
| IL (1) | IL160371A0 (es) |
| MX (1) | MXPA04001805A (es) |
| NO (1) | NO20040857L (es) |
| SE (1) | SE0102887D0 (es) |
| WO (1) | WO2003017983A1 (es) |
| ZA (1) | ZA200401547B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1904067B2 (en) * | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| WO2007055329A1 (ja) | 2005-11-11 | 2007-05-18 | Asahi Kasei Chemicals Corporation | 徐放性固形製剤 |
| GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| ES2459322T3 (es) | 2008-09-05 | 2014-05-09 | Supernus Pharmaceuticals, Inc. | Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH) |
| EP2780016A4 (en) * | 2011-11-07 | 2015-08-05 | Diakron Pharmaceuticals Inc | EXTENDED RELEASE FORMULATION OF DIRECT THROMBIN INHIBITOR |
| WO2013119794A1 (en) * | 2012-02-08 | 2013-08-15 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
| US10071058B2 (en) * | 2012-03-07 | 2018-09-11 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
| GB8624213D0 (en) * | 1986-10-09 | 1986-11-12 | Sandoz Canada Inc | Sustained release pharmaceutical compositions |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| SE510305C2 (sv) * | 1997-05-30 | 1999-05-10 | Astra Ab | Nytt salt |
| MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
-
2001
- 2001-08-29 SE SE0102887A patent/SE0102887D0/xx unknown
-
2002
- 2002-08-28 US US10/488,125 patent/US20040197404A1/en not_active Abandoned
- 2002-08-28 CA CA002457341A patent/CA2457341A1/en not_active Abandoned
- 2002-08-28 BR BR0212167-0A patent/BR0212167A/pt not_active IP Right Cessation
- 2002-08-28 MX MXPA04001805A patent/MXPA04001805A/es unknown
- 2002-08-28 HU HU0401599A patent/HUP0401599A3/hu unknown
- 2002-08-28 IL IL16037102A patent/IL160371A0/xx unknown
- 2002-08-28 EP EP02763155A patent/EP1423099A1/en not_active Withdrawn
- 2002-08-28 KR KR10-2004-7002920A patent/KR20040032977A/ko not_active Application Discontinuation
- 2002-08-28 CN CNA028168712A patent/CN1549705A/zh active Pending
- 2002-08-28 WO PCT/SE2002/001541 patent/WO2003017983A1/en not_active Application Discontinuation
- 2002-08-28 JP JP2003522503A patent/JP2005504052A/ja active Pending
-
2004
- 2004-02-25 ZA ZA200401547A patent/ZA200401547B/en unknown
- 2004-02-26 NO NO20040857A patent/NO20040857L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200401547B (en) | 2004-11-17 |
| CN1549705A (zh) | 2004-11-24 |
| HUP0401599A2 (hu) | 2004-11-29 |
| US20040197404A1 (en) | 2004-10-07 |
| CA2457341A1 (en) | 2003-03-06 |
| KR20040032977A (ko) | 2004-04-17 |
| NO20040857L (no) | 2004-04-19 |
| EP1423099A1 (en) | 2004-06-02 |
| IL160371A0 (en) | 2004-07-25 |
| WO2003017983A1 (en) | 2003-03-06 |
| JP2005504052A (ja) | 2005-02-10 |
| BR0212167A (pt) | 2004-07-20 |
| HUP0401599A3 (en) | 2007-03-28 |
| SE0102887D0 (sv) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA88270C2 (ru) | Фармацевтический препарат и его применение для профилактики удара, диабета | |
| IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
| RS20050344A (en) | Treatment for hemorrhagic shock | |
| HK1068606A1 (en) | Novel aminobenzoephenones | |
| SG146638A1 (en) | Pharmaceutical delivery system | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| WO2005062898A3 (en) | Enhanced absorption of modified release dosage forms | |
| MXPA04001805A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
| HUP0203682A2 (hu) | Eljárás foszfodiészteráz-4 inhibitor beadására | |
| WO2005004854A3 (fr) | Utilisation de la betaine pour le traitement des arterites | |
| GB0020504D0 (en) | Therapeutic method | |
| SE9902597D0 (sv) | New use | |
| MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
| HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
| MXPA04001812A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| SE0102888D0 (sv) | New formulation | |
| TW200502002A (en) | A new oral immediated release dosage form | |
| HK1075390A1 (en) | Citalopram for the treatment of elevated blood pressure | |
| GB0129962D0 (en) | Method of treatment | |
| TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
| MD2491F1 (en) | Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment | |
| MXPA03010920A (es) | Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia. | |
| NZ514490A (en) | Method and means for treating post-polio syndrome | |
| UA42427A (uk) | Спосіб корекції целюліту та/або локальних жирових відкладень |